RayKnowChina Research Map
Shortlist

NanjingNanjing Medical University

Jiangsu Cancer Hospital

江苏省肿瘤医院

Listed for 8 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Jiangsu Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌14 papers led1 open trial led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌25 papers led2 open trials led
  3. Hepatocellular carcinoma肝细胞癌16 papers led
  4. Stomach cancer胃癌26 papers led
  5. Osteosarcoma骨肉瘤0 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  8. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 14 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
14
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 3320232024: 4420242025: 332025

4 hospitals in Nanjing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT05912582

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  2. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  3. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIRecurrent / metastatic diseaseRadiotherapy technique
Departments in papersRadiation oncologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led14
  1. The Role of Ubiquitination Regulation in Nasopharyngeal Carcinoma.2026Cancer investigation
  2. Lactic Acid Metabolism-Related Gene May Act as a Prognostic Predictor by FARS2 in Nasopharyngeal Carcinoma.2025American journal of rhinology & allergy
  3. CircINADL promotes nasopharyngeal carcinoma metastasis by inhibiting HuR ubiquitin degradation and disrupting the hippo signaling pathway.2025Cellular signalling
  4. miR-205-5p Promotes the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells by Regulating CALM1.2025Critical reviews in immunology
  5. Long-term follow-up of protective effects on salivary and swallowing structures and improvement of late xerostomia and dysphagia by level IIb optimisation in clinical target volume of nasopharyngeal carcinoma.2024BMC cancerFree full text
  6. A pretreatment multiparametric MRI-based radiomics-clinical machine learning model for predicting radiation-induced temporal lobe injury in patients with nasopharyngeal carcinoma.2024Head & neck
  7. Effects of ambient temperature, relative humidity and absolute humidity on risk of nasopharyngeal carcinoma in China.2024International journal of cancer
  8. Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1hi and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.2024Oral oncology
  9. Depletion of SOD2 enhances nasopharyngeal carcinoma cell radiosensitivity via ferroptosis induction modulated by DHODH inhibition.2023BMC cancerFree full text
  10. METTL3-stabilized super enhancers-lncRNA SUCLG2-AS1 mediates the formation of a long-range chromatin loop between enhancers and promoters of SOX2 in metastasis and radiosensitivity of nasopharyngeal carcinoma.2023Clinical and translational medicineFree full text
  11. LINC01376 promotes nasopharyngeal carcinoma tumorigenesis by competitively binding to the SP1/miR-4757/IGF1 axis.2023IUBMB life
  12. CircFOXM1 acts as a ceRNA to upregulate SMAD2 and promote the progression of nasopharyngeal carcinoma.2022Molecular genetics & genomic medicineFree full text
  13. Long non-coding RNA LUADT1 promotes nasopharyngeal carcinoma cell proliferation and invasion by downregulating miR-1207-5p.2021BioengineeredFree full text
  14. LncRNA EPB41L4A-AS2 represses Nasopharyngeal Carcinoma Metastasis by binding to YBX1 in the Nucleus and Sponging MiR-107 in the Cytoplasm.2021International journal of biological sciencesFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal CarcinomaNot yet recruitingNCT05912582Lead sponsorStart 2025-12
  2. Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal CarcinomaCompletedNCT06244394Lead sponsorStart 2023-06
  3. NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent ChemoradiationTerminatedNCT01694576Lead sponsorPhase 2Start 2012-09
  4. Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)CompletedNCT01712919Lead sponsorPhase 1/Phase 2Start 2010-05
  5. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  6. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  7. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  8. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  9. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Study sitePhase 3Start 2015-01
More papers found outside PubMed (not counted)26
  1. 1377P TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial2025Annals of Oncologyarticle
  2. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  3. Cisplatin-polyphenol complex liposomes reduce chemotherapy toxicity2025Chinese Chemical Lettersarticle
  4. Compare the Predictive Performance of Deep Learning and Radiomics Models for Predicting Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Correlation between family care and stigma in patients undergoing radiotherapy for nasopharyngeal carcinoma: a retrospective observational analysis2024Chirurgiaarticle
  6. Deep Transfer Learning and Dosiomics for Predicting Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncologyconference-abstract
  8. LncRNA C7orf13 facilitates cell proliferation and metastasis in nasopharyngeal carcinoma via targeting miR ‐449c/ miR ‐28‐5p‐ FMNL2 axis2024Precision Medical Sciencesarticle
  9. A summary of our serial study: mechanism of invasion and metastasis in nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  10. Application and effect evaluation of case management nursing practice mode in patients with precision radiotherapy for nasopharyngeal carcinoma2023Precision Medical Sciencesarticle
  11. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  12. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  13. A case report of hypocalcemia after chemotherapy with albumin‐bound paclitaxel2022Precision Medical Sciencesarticle
  14. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Researchconference-abstract
  15. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  16. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  17. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  18. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  19. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  20. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  21. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  22. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  23. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  24. Effect of ear exercises on hearing loss in patients with nasopharyngeal carcinoma after radiotherapy2022Precision Medical Sciencesarticle
  25. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncologyconference-abstract
  26. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 25 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
25
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 2220212022: 5520222023: 1120232024: 8820242025: 882025

5 hospitals in Nanjing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07435454

    Age 70 years to Not stated (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  2. Enrolling by invitation
    Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT07016737

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  3. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  4. Recruiting
    Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07530094

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  5. Recruiting
    Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
    Phase
    N/A
    Started
    2020-01
    Registry
    NCT04519905

    Age 76 years to Not stated (registered criteria)

    Led by Huadong Hospital, Fudan University; 1 listed hospital as study siteNanjing, Shanghai

  6. Recruiting
    Chemoradiotherapy in Unresectable Esophageal Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-10
    Registry
    NCT04278287

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyNeoadjuvant & combined treatmentRadiotherapy
Departments in papersRadiation oncologyMedical oncologyRadiology / nuclear medicine
Papers it led25
  1. Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders.2026Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  2. Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study.2025BMC cancerFree full text
  3. Application of Esophageal Sponge Cytology in Screening Esophageal Squamous Cell Carcinoma in a High-Risk Region of China.2025Cancer medicineFree full text
  4. Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  5. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge in advanced esophageal squamous cell carcinoma: A retrospective study.2025Human vaccines & immunotherapeuticsFree full text
  6. USP49 undergoes liquid-liquid phase separation and stabilizes RPA70 to induce radioresistance through homologous recombination repair in esophageal squamous cell carcinoma.2025International journal of biological macromolecules
  7. Pathological responses to neoadjuvant immunochemotherapy: implications for survival and recurrence in patients with locally advanced esophageal squamous cell carcinoma.2025Journal of translational medicineFree full text
  8. lncRNA FENDRR Predicts Adverse Prognosis and Regulates the Development of Esophageal Squamous Cell Carcinoma Through Negatively Modulating miR-495-3p.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  9. Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First-Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study.2025Thoracic cancerFree full text
  10. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study.2024Cancer medicineFree full text
  11. Kinetics of plasma cell-free DNA as a prospective biomarker to predict the prognosis and radiotherapy effect of esophageal cancer.2024Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  12. Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer.2024International immunopharmacology
  13. Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study.2024International immunopharmacology
  14. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial.2024Journal for immunotherapy of cancerFree full text
  15. Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older.2024Radiation oncology (London, England)Free full text
  16. Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.2024Technology in cancer research & treatmentFree full text
  17. Complete responses after neoadjuvant toripalimab and chemoradiotherapy for oesophageal squamous cell carcinoma: in situ and ex vivo 3.0 T MRI assessment.2024The British journal of surgery
  18. circFNDC3B promotes esophageal squamous cell carcinoma progression by targeting MYO5A via miR-370-3p/miR-136-5p.2023BMC cancerFree full text
  19. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.2022ESMO openRCTFree full text
  20. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.2022Frontiers in immunologyFree full text
  21. PELI1 promotes radiotherapy sensitivity by inhibiting noncanonical NF-κB in esophageal squamous cancer.2022Molecular oncologyFree full text
  22. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.2022Radiation oncology (London, England)Free full text
  23. Tertiary lymphoid structures favor outcome in resected esophageal squamous cell carcinoma.2022The journal of pathology. Clinical researchFree full text
  24. CircIMMP2L promotes esophageal squamous cell carcinoma malignant progression via CtBP1 nuclear retention dependent epigenetic modification.2021Clinical and translational medicineFree full text
  25. Tumor-infiltrating plasma cells are the promising prognosis marker for esophageal squamous cell carcinoma.2021Esophagus : official journal of the Japan Esophageal Society
Chinese-language papers (not in the count)1
  1. [Efficacy and safety of PD-1 inhibitors combined with chemotherapy for the treatment of local recurrence at the primary tumor site of ESCC following definitive chemoradiotherapy or radiotherapy].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status18
  1. Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07435454Lead sponsorPhase 2Start 2025-12
  2. Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of EsophagusStatus unknownNCT05424432Lead sponsorPhase 2Start 2022-04
  3. Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCCStatus unknownNCT05394415Lead sponsorPhase 1/Phase 2Start 2022-05
  4. Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive ChemoradiotherapyEnrolling by invitationNCT07016737Lead (inferred)Phase 3Start 2024-08
  5. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  6. Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07530094Study sitePhase 2Start 2025-12
  7. Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)RecruitingNCT04519905Study siteN/AStart 2020-01
  8. Chemoradiotherapy in Unresectable Esophageal CancerRecruitingNCT04278287Study sitePhase 1/Phase 2Start 2019-10
  9. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  10. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  11. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  12. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  13. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Study sitePhase 3Start 2020-02
  14. Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal CarcinomaStatus unknownNCT03790553Study sitePhase 3Start 2018-10
  15. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  16. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  17. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
  18. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Study sitePhase 3Start 2015-03
More papers found outside PubMed (not counted)31
  1. 2120P Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. 2167P Comparative immune-pathological responses to neoadjuvant chemoimmunotherapy and chemotherapy in esophageal squamous cell carcinoma and development of a prognostic model2025Annals of Oncologyarticle
  3. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  4. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Nanoparticle polymeric micellar paclitaxel compared with paclitaxel for advanced esophageal squamous cell carcinoma2025Precision Medical Sciencesarticle
  6. Real-world effectiveness and safety of first-line serplulimab in patients with metastatic or locally advanced esophageal carcinoma.2025Journal of Clinical Oncologyarticle
  7. The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-N2025Journal of Clinical Oncologyarticle
  8. Tislelizumab plus short-course chemo-radiotherapy for conversion therapy of unresectable ESCC (LATE): A proof-of-concept, phase Ib trial.2025Journal of Clinical Oncologyarticle
  9. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncologyretraction
  10. 188P The impact of pathological regression of primary tumor and lymph node on recurrence and survival in patients with locally advanced esophageal squamous cell carcinoma following neoadjuvant chemo-immunotherapy2024Annals of Oncologyarticle
  11. Abstract LB003: Comprehensive multi-omics analysis unveils NFE2L2/KEAP1 mutations as key drivers of treatment resistance in esophageal squamous cell carcinoma during chemoradiotherapy2024Cancer Researchconference-abstract
  12. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.2024Journal of Clinical Oncologyconference-abstract
  13. Effectiveness and safety of first-line serplulimab in patients with metastatic/locally advanced esophageal carcinoma (EC): A real-world study.2024Journal of Clinical Oncologyconference-abstract
  14. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  15. Impact of immunotherapy combined with neoadjuvant chemotherapy or chemoradiotherapy on perioperative safety in locally advanced esophageal squamous cell carcinoma (LA-ESCC): A retrospective propensity score-matched analysis.2024Journal of Clinical Oncologyconference-abstract
  16. Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.2024Journal of Clinical Oncologyconference-abstract
  17. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncologyarticle
  18. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Researchconference-abstract
  19. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  20. Association of PIWI-interacting RNA-23210 with tumor metastasis in esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  21. Identification of secretory factors associated with suppressive tumor microenvironment in esophageal cancer2023Research Squarepreprint
  22. P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncologyconference-abstract
  23. Two cycles versus four cycles of neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, multicenter and randomized study.2023Journal of Clinical Oncologyconference-abstract
  24. 132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)2022Annals of Oncologyarticle
  25. Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).2022Journal of Clinical Oncologyconference-abstract
  26. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  27. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  28. SCALE-1: Safety and efficacy of short course neoadjuvant chemo-radiotherapy plus toripalimab for locally advanced resectable squamous cell carcinoma of esophagus.2022Journal of Clinical Oncologyconference-abstract
  29. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  30. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncologyconference-abstract
  31. Phase-II study of toripalimab combined with neoadjuvant chemotherapy for the treatment of resectable esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 16 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 5520232024: 2220242025: 332025

7 hospitals in Nanjing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led16
  1. Nicotinamide metabolism affects the prognosis of hepatocellular carcinoma by influencing the tumor microenvironment.2025Cytokine
  2. Targeting HCG18 counteracts ferroptosis resistance via blocking the miR-30a-5p/RRM2/GSS pathway in hepatocellular carcinoma.2025International journal of biological sciencesFree full text
  3. Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study.2025Investigational new drugsFree full text
  4. Bile acid conjugated chitosan nanoparticles promote the proliferation and epithelial-mesenchymal transition of hepatocellular carcinoma by regulating the PI3K/Akt/mTOR pathway.2024Carbohydrate research
  5. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.2024Journal of gastroenterology and hepatology
  6. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.2023Advances in therapy
  7. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.2023Cancer biomarkers : section A of Disease markersFree full text
  8. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.2023Cancer medicineFree full text
  9. A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.2023Frontiers in immunologyFree full text
  10. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC.2023Hepatology (Baltimore, Md.)Free full text
  11. Egr1/HSP70 Promoter-Driven Activation of Gene Expression for Synergistic Anti-Hepatoma Using PEI-MZF Nanoparticles and Radiation.2022International journal of nanomedicineFree full text
  12. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma.2022Journal for immunotherapy of cancerFree full text
  13. Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3.2021AgingFree full text
  14. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress.2021Cellular oncology (Dordrecht, Netherlands)Free full text
  15. Combination of Tertiary Lymphoid Structure and Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients With Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  16. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.2021TheranosticsFree full text
All its trials on ClinicalTrials.gov, any status6
  1. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  2. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  3. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  4. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  5. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  6. Axitinib For The Treatment Of Advanced Hepatocellular CarcinomaCompletedNCT01210495Study sitePhase 2Start 2010-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 26 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
26
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 3320212022: 7720222023: 3320232024: 3320242025: 992025

8 hospitals in Nanjing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  3. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  4. Not yet recruiting
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07902596

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsSurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led26
  1. tRF-Ser-TGA-011 impedes gastric cancer progression by targeting the MAP3K13/JNK signaling cascade.2026Cellular signalling
  2. Silencing of RNFT2 suppresses cell proliferation and migration through mTORC1 signaling pathway in gastric cancer.2025Amino acidsFree full text
  3. The levels of plasma MiR-9 and MiR-106a are associated with the development of peritoneal carcinomatosis in patients with gastric cancer.2025BMC cancerFree full text
  4. The efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for locally advanced gastric cancer: a single-center, real-world clinical study.2025Cancer immunology, immunotherapy : CIIFree full text
  5. COL1A1-positive endothelial cells promote gastric cancer progression via the ANGPTL4-SDC4 axis driven by endothelial-to-mesenchymal transition.2025Cancer letters
  6. Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer.2025Cancer research
  7. Unveiling the Power of Mitochondrial Fission and Fusion: A Five- Gene Signature for Personalized Prognosis in Gastric Cancer.2025Current medicinal chemistry
  8. N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  9. Tunnel anastomosis: a modified flap technique in esophagogastrostomy as a novel antireflux technique after proximal gastrectomy.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  10. Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer.2025World journal of surgical oncologyFree full text
  11. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13+CD103+CD8+ Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy.2024Gastroenterology
  12. Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study.2024Human vaccines & immunotherapeuticsFree full text
  13. Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer.2024Journal of gastrointestinal cancerFree full text
  14. Construction and evaluation of the functional polygenic risk score for gastric cancer in a prospective cohort of the European population.2023Chinese medical journalFree full text
  15. Quantitative parameters in novel spectral computed tomography for assessing gastric cancer and cell proliferation.2023European journal of radiology
  16. Biomimetic black phosphorus nanosheets codeliver CDK9 and BRD4 inhibitors for gastric cancer targeted therapy.2023Journal of materials chemistry. B
  17. Proximal gastrectomy may be a reasonable choice for patients with selected proximal advanced gastric cancer: A propensity score-matched analysis.2022Asian journal of surgery
  18. Deep muscularis propria tumor invasion without lymph node metastasis as a unique subclassification of stage IB gastric cancer: a retrospective study.2022BMC gastroenterologyFree full text
  19. Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer.2022Cancer immunology research
  20. tRF-Val-CAC-016 modulates the transduction of CACNA1d-mediated MAPK signaling pathways to suppress the proliferation of gastric carcinoma.2022Cell communication and signaling : CCSFree full text
  21. A novel monoclonal antibody associated with glucoside kills gastric adenocarcinoma AGS cells based on glycosylation target.2022Journal of cellular and molecular medicineFree full text
  22. MiR-200a-3p promotes gastric cancer progression by targeting DLC-1.2022Journal of molecular histology
  23. Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer.2022Life sciences
  24. Down-regulation of estrogen-related receptor alpha (ERRα) inhibits gastric cancer cell migration and invasion in vitro and in vivo.2021AgingFree full text
  25. MiR-200c-3p aggravates gastric cell carcinoma via KLF6.2021Genes & genomicsFree full text
  26. Clinicopathological features and risk factors analysis of lymph node metastasis and long-term prognosis in patients with synchronous multiple gastric cancer.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Efficacy and feasibility of tunnel esophagogastrostomy to perform proximal gastrectomy].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status22
  1. Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric AdenocarcinomaStatus unknownNCT05237349Lead (inferred)Phase 2Start 2022-03
  2. A Benefit Population Atlas of nICT Versus nCT for LAGCCompletedNCT07098104Lead (inferred)Start 2019-11
  3. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  4. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  5. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ AdenocarcinomaNot yet recruitingNCT07902596Study siteStart 2026-10
  6. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  7. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  8. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  9. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  10. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  11. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  12. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Study sitePhase 3Start 2018-01
  13. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  14. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  15. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06
  16. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  17. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)CompletedNCT02745509Study siteN/AStart 2016-03
  18. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  19. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  20. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  21. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  22. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

25 hospitals in Nanjing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

11 hospitals in Nanjing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Nanjing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Nanjing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

江苏省肿瘤医院

Jiangsu Cancer Hospital

南京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Affiliated Cancer Hospital of Nanjing Medical University; Nanjing Medical University Affiliated Cancer Hospital; Jiangsu Cancer Hospital Affiliated to Nanjing Medical University; Affiliated Cancer Hospital ( Jiangsu Cancer Hospital); Jiangsu Cancer Centre; Jiangsu Provincial Cancer Hospital; Affiliated Cancer Hospital (Jiangsu Cancer Hospital); Jiangsu Cancer Hosiptal

Suggest a correctionDownload the data